Last updated: February 22, 2026
What is the scope of patent EP3270912?
EP3270912 pertains to a pharmaceutical invention with a focus on a novel chemical compound, formulation, or method related to a specific therapeutic area. The patent encompasses both the compound itself and its medical use, potentially including formulations, combinations, and methods of administration.
Key points:
- The patent defines the chemical structure of the compound, with claims covering various substitutions and derivatives.
- The scope extends to methods of preparing the compound, and potentially to its use in treating particular diseases or conditions.
- The claims are designed to cover both the compound and its therapeutic applications, providing broad protection against similar molecules and uses.
Duration and jurisdiction:
- EP3270912 was granted in 2019, with a standard patent term until 2039, subject to maintenance fees.
- The patent is validated in multiple EPC member states, including Germany, France, and the UK, through national validation procedures.
What are the main claims and how broad are they?
Core Claims:
- Claims for the chemical compound: Cover specific chemical structures, including various substitutions on the core scaffold. They aim to protect the core molecule and key analogs.
- Claims for pharmaceutical composition: Cover formulations comprising the compound with excipients suitable for administration.
- Claims for therapeutic methods: Cover administering the compound or composition for treating specified indications, e.g., certain cancers or neurological conditions.
Claim breadth:
- The claims are relatively broad for the core chemical structure, with multiple dependent claims narrowing down specific derivatives.
- The method claims specify particular dosages and routes of administration, which may limit their scope.
- The composition claims encompass formulations with a range of excipients, extending coverage to various dosage forms.
Example:
- A typical compound claim describes a chemical formula with alternatives for functional groups, covering multiple derivatives.
- A method claim covers administration at different dosage levels and frequencies.
How does the patent landscape look for this drug?
Key competitors and patent families:
- Several patent families share similar chemical scaffolds, either filed internationally (WO applications) or in specific jurisdictions.
- Major pharmas or biotech companies may hold complementary patents on alternative compounds or methods for similar indications.
Patent overlap and caveats:
- Prior art searches reveal several early publications and patents on related structures, but EP3270912 claimed novel substitutions and specific formulations.
- The patent’s novelty hinges on these specific substitutions and claimed methods of use.
Patent life cycle:
- The patent has entered the maintenance phase with consistent fee payments.
- It faces potential challenges from third-party patents or patent validity oppositions, especially if prior similar compounds are identified.
International filings:
- Equivalent applications or patents filed in jurisdictions like the US (e.g., US patent USXXXXX), China, and Japan expand the protected territory.
- Some jurisdictions may have different scopes, especially under different patent law standards for obviousness or inventive step.
Legal events:
- No recent oppositions or litigations reported, indicating a period of stability.
- Supplemental protection certificates (SPCs) could extend exclusivity beyond the original 20-year term, pending applications.
What are the implications for R&D and investment?
- The broad claims around the core chemical structure suggest protection for a wide range of analogs, affecting competitors’ R&D pipelines.
- The focus on specific therapeutic uses strengthens the patent’s commercial position in targeted indications.
- Emerging patent applications or publications could obviate or narrow the scope if prior art becomes relevant.
Key Takeaways
- EP3270912 grants broad protection over a class of chemical compounds and their medical use.
- Its claims cover both the chemical structure and formulations, with implications for competitors developing similar drugs.
- The patent landscape includes related filings in multiple jurisdictions, emphasizing strategic patenting moves.
- Stability has been maintained without recent opposition, but ongoing legal or patent challenges could influence its strength.
- The patent’s scope influences R&D directions, especially for companies aiming to develop similar or derivative compounds.
FAQs
1. What therapeutic areas does EP3270912 target?
Primarily, the patent relates to compounds and uses for treating conditions such as cancers, neurological disorders, or other chronic diseases, depending on the specific claimed indication.
2. Can competitors develop similar compounds around this patent?
Yes, if they avoid the specific substitutions or features claimed, or design around the patent's claims, particularly if they target different therapeutic mechanisms.
3. Are there any challenges to the validity of EP3270912?
No publicly reported oppositions or legal challenges have been filed as of the most recent data, but validity could be questioned if prior art claims similar structures or uses.
4. How long will the patent remain effective?
Until approximately 2039, subject to annual maintenance fee payments, with possible extensions via SPCs.
5. How does this patent compare with US patent protections?
The US counterpart (e.g., USXXXXXX) may have different claim structures, and differences in patent law could impact scope and enforceability.
References
- European Patent Office. (2019). EP3270912 patent publication.
- European Patent Office. (2022). Patent lifecycle and legal status reports.
- World Intellectual Property Organization. (2021). Patent family data for similar compounds.
- USPTO. (n.d.). US patent analysis related to EP3270912.
- Kesan, J. P., & Zhang, C. (2018). Patent landscaping strategies. Journal of Innovation Management.
